<div id="readability-page-1"><p>Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have been given a consensus recommendation of &#34;Hold&#34; by the thirteen analysts that are presently  covering the company, MarketBeat.com reports. One analyst  has rated the stock with a sell recommendation, ten have issued  a hold recommendation, one  has issued  a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $48.4444.</p><div><p><span></span><span>Get <strong>Rapt Therapeutics</strong> alerts:</span></p></div><p>A number of analysts have issued reports on the company. HC Wainwright downgraded Rapt Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $58.00 target price for the company. in a research note on Tuesday, January 20th. Clear Str lowered shares of Rapt Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 20th. Barclays downgraded shares of Rapt Therapeutics from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $58.00 target price on the stock. in a research note on Wednesday, January 21st. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Rapt Therapeutics in a research note on Thursday, January 22nd. Finally, TD Cowen downgraded shares of Rapt Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 20th.</p><p><b>Get Our Latest Stock Analysis on Rapt Therapeutics</b></p><h2>Institutional Investors Weigh In On Rapt Therapeutics</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP raised its holdings in  Rapt Therapeutics by 173.4% in the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock valued at $1,170,000 after buying an additional 28,782 shares during the period.  Millennium Management LLC boosted its stake in  Rapt Therapeutics by 75.2% during the third quarter. Millennium Management LLC now owns 39,278 shares of the company's stock worth $1,013,000 after buying an additional 16,854 shares during the period.  Ameriprise Financial Inc. acquired a new stake in shares of  Rapt Therapeutics during the third quarter valued at about $1,326,000.  Bridgeway Capital Management LLC raised its stake in shares of  Rapt Therapeutics by 32.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company's stock valued at $532,000 after acquiring an additional 5,000 shares during the period.  Finally, UBS Group AG lifted its holdings in shares of  Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company's stock worth $743,000 after acquiring an additional 25,116 shares during the last quarter. Hedge funds and other institutional investors own  99.09% of the company's stock. </p><h2>Rapt Therapeutics Trading Up 0.0%</h2><p>RAPT stock opened at $57.69 on Friday. The firm has a 50-day moving average of $40.61 and a two-hundred day moving average of $27.98. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $57.86. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.22 and a beta of 0.47. </p><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.23.  As a group, equities analysts forecast that  Rapt Therapeutics will post -2.14 earnings per share for the current year. </p><h2>Rapt Therapeutics Company Profile</h2> (Get Free Report)<p>RAPT Therapeutics, Inc <span>NASDAQ: RAPT<span></span></span> is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.  </p><p>The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Rapt Therapeutics</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The $650 Million Bet on AI's Future</li><li>The gold chart Wall Street is terrified of…</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>Your Bank Account Is No Longer Safe</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p><p>While Rapt Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rapt Therapeutics (NASDAQ:RAPT) has received a consensus recommendation of "Hold" from thirteen analysts. The ratings include one sell, ten hold, one buy, and one strong buy. The average target price is $48.44. Recent downgrades include HC Wainwright and TD Cowen, while institutional investors have increased their stakes significantly. RAPT's stock opened at $57.69, with a market cap of $1.60 billion and a P/E ratio of -5.22. The company focuses on developing therapeutics for autoimmune and allergic diseases, with its lead asset RPT193 in clinical development.</p>

Market Beat

Health Care Select Sector SPDR

VG Health

iShares US Pharma

RAPT Therapeutics

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts